Carrot Fertility vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
Carrot Fertility is a global fertility benefits platform offering employers customizable coverage for IVF, adoption, surrogacy, menopause, and low-cost medication through 50+ countries.
About
Carrot Fertility is a global fertility and family-forming benefits company founded in 2016 by Tammy Sun, raising over $100M to build the most comprehensive employer fertility benefits platform globally. The company offers employers a highly customizable benefits program covering IVF, egg freezing, donor services, adoption, gestational surrogacy, menopause care, and gender-affirming family building across 50+ countries. Carrot operates a digital-first model that connects members with clinical resources, care navigation, and financial support rather than owning a proprietary clinic network. The platform integrates with leading fertility clinics and medication pharmacies to provide members access to vetted care at competitive prices, including a Carrot Rx program that sources fertility medications at significantly below-retail prices. Carrot serves hundreds of employers including major technology companies, professional services firms, and global corporations that want inclusive fertility benefits covering all paths to parenthood. The company competes with Progyny and Kindbody in the US employer fertility benefits market while leading in global coverage for international employers with diverse workforces across multiple countries.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Carrot Fertility vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.